Status:
COMPLETED
AGN 201904 Versus Esomeprazole in the Prevention of Aspirin-induced Stomach or Upper Intestinal Damage in Healthy Volunteers
Lead Sponsor:
Allergan
Conditions:
Peptic Ulcer
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
AGN 201904, a proton pump inhibitor, versus esomeprazole in the prevention of stomach or upper intestinal damage following administration of high-dose aspirin in healthy volunteers
Eligibility Criteria
Inclusion
- Healthy Adult Volunteers who have provided written informed consent
Exclusion
- Volunteers with a history of upper gastrointestinal disease or who have a current diagnosis of upper gastrointestinal disease.
- Female volunteers who pregnant, nursing, or planning a pregnancy
- Volunteers with a history of drug or alcohol abuse
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2006
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00325715
Start Date
April 1 2006
End Date
August 1 2006
Last Update
June 2 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Houston, Texas, United States